Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient
Ann Hematol
.
2023 Aug;102(8):2283-2284.
doi: 10.1007/s00277-023-05265-8.
Epub 2023 May 15.
Authors
Julia Bini Viotti
1
2
,
Fabian Dammann
1
2
,
Antonio Martin Jimenez Jimenez
3
,
Anthony D Anderson
4
,
Michele I Morris
2
,
Jose F Camargo
2
,
Mohammed Raja
5
Affiliations
1
Jackson Health System, Miami Transplant Institute, Miami, FL, USA.
2
Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
3
Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
4
Department of Pharmacy Services, University of Miami Miller School of Medicine, Miami, FL, USA.
5
Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. mxr1829@med.miami.edu.
PMID:
37183208
DOI:
10.1007/s00277-023-05265-8
No abstract available
Publication types
Letter
MeSH terms
Antiviral Agents / therapeutic use
Cytomegalovirus Infections* / drug therapy
Hematopoietic Stem Cell Transplantation*
Humans
Transplant Recipients
Substances
maribavir
Antiviral Agents